Metabolites News and Research

RSS

High prevalence of type 2 diabetes may be linked to excess niacin intake

Facing the increasing prevalence of type 2 diabetes worldwide in the past few decades, one may ask what is wrong with humans. Geneticists tell us that the human genome has not changed markedly in such a short time.

23 Dec 2009

Winner of the 2010 Avanti Award in Lipids

The 2010 Avanti Award in Lipids, which recognizes outstanding research contributions in the area of lipid research, has been awarded to David W. Russell, the Eugene McDermott distinguished chair of molecular genetics at the University of Texas Southwestern Medical Center at Dallas.

11 Dec 2009

Patients' urine may provide rapid diagnosis of pneumonia

Doctors may soon be able to quickly and accurately diagnose the cause of pneumonia-like symptoms by examining the chemicals found in a patient's urine, suggests a new study led by UC Davis biochemist Carolyn Slupsky.

10 Dec 2009

Scientists discover the potential basis for urine test to diagnose CAP

Scientists are reporting a discovery of the potential basis for a urine test to diagnose community-acquired pneumonia (CAP), a difficult-to-diagnose disease that is the sixth leading cause of death in the United States.

10 Dec 2009

MCG receives $1.8M stimulus grant

It's a $1.8 million shot in the arm to the largest grant the Medical College of Georgia has ever received.

8 Dec 2009

People who smoke immediately after waking up face high risk of lung cancer

People who smoke their first cigarette within minutes after waking up have much higher levels of cotinine, a by-product of nicotine when processed by the body, than those who wait to smoke, regardless of the number of cigarettes smoked.

3 Dec 2009

Over twenty new drug metabolism assays launched by Absorption Systems

Absorption Systems, a leader in drug safety and ADMET (absorption, distribution, metabolism, excretion and toxicity) testing, today announced the introduction of a more complete series of drug metabolism assays designed to support the pharmaceutical R&D process, from early-stage discovery through late-stage clinical development.

2 Dec 2009

Study: Impaired oxidation in liver associated with progression to nonalcoholic steatohepatitis

A recent metobolomics study by researchers from Virginia Commonwealth University Medical Center in Richmond found that impaired peroxisomal oxidation of polyunsaturated fatty acids (PUFA) is associated with the progression of nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH).

24 Nov 2009

Mutated IDH1 gene linked to the progression of gliomas

23 Nov 2009

Mutated IDH1 gene has novel enzyme activity consistent with cancer-causing gene: Study

Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene. This breakthrough discovery shows that the mutated form of IDH1 produces a metabolite, 2-hydroxyglutarate (2HG), which may contribute to the formation and malignant progression of gliomas, the most common type of brain cancers.

23 Nov 2009

New report finds positive association between phthalate exposure and ADHD symptoms

Phthalates are important components of many consumer products, including toys, cleaning materials, plastics, and personal care items. Studies to date on phthalates have been inconsistent, with some linking exposure to these chemicals to hormone disruptions, birth defects, asthma, and reproductive problems, while others have found no significant association between exposure and adverse effects.

19 Nov 2009

Fetal exposure to phthalates has the potential to alter masculine brain development: Study

A study of 145 preschool children reports, for the first time, that when the concentrations of two common phthalates in mothers' prenatal urine are elevated their sons are less likely to play with male-typical toys and games, such as trucks and play fighting.

16 Nov 2009

Millennium Laboratories announces new clinical quantitative assay and drug screening tests for healthcare

Millennium Laboratories, a leading provider of therapeutic drug monitoring and education to physicians and staff treating chronic pain patients, announced today the company’s development and validation of a clinical quantitative assay for the new drug tapentadol (Nucynta™) by liquid chromatography/tandem mass spectrometry (LC-MS/MS).

12 Nov 2009

NIDA supports new drug detection research

Every time a person snorts cocaine, it doesn't just go to his or her head: It also provokes a response in the immune system, creating special biomolecules that may serve as a permanent record of each exposure.

11 Nov 2009

New imagining technique may yield better antiviral and anti-cancer drugs

A recently devised method of imaging the chemical communication and warfare between microorganisms could lead to new antibiotics, antifungal, antiviral and anti-cancer drugs, said a Texas AgriLife Research scientist.

10 Nov 2009

NIH grant to develop a new method for rapidly screening blood samples for biomarkers

Dr. Jennifer Brodbelt, professor of chemistry and biochemistry at The University of Texas at Austin, has received a $734,068 grant from the National Institutes of Health (NIH) to develop a new method for rapidly screening blood samples for biomarkers.

5 Nov 2009

NCI awards $4.8M for project to measure all the proteins in the human body

An expert in cancer proteomics at Fred Hutchinson Cancer Research Center has received $4.8 million in federal stimulus funding from the National Cancer Institute to co-lead a pilot study to assess the feasibility and scalability of a project that aims to measure all of the proteins in the human body.

31 Oct 2009

Clinical data on the validation set 'Alzheimer patients versus healthy controls' for AclarusDx presented

ExonHit Therapeutics yesterday presented clinical data on the validation set “Alzheimer patients versus healthy controls” for AclarusDx™ (formerly EHT Dx21), its blood-based diagnostic test for the detection of Alzheimer’s disease (AD), at the 2nd Conference of Clinical Trials on Alzheimer’s Disease (CTAD) in Las Vegas, USA.

30 Oct 2009

Cardiome Pharmam, Astellas Pharma begin patient enrolment for ACT 5 trial

Cardiome Pharma Corp. and its co-development partner Astellas Pharma US, Inc. ("Astellas") announced today that patient enrolment has begun for the ACT 5 trial, a confirmatory Phase 3 clinical trial of KYNAPID(TM) (vernakalant hydrochloride) Injection, a drug product candidate under development for the rapid conversion of atrial fibrillation to sinus rhythm.

29 Oct 2009